Dihydroquinolinones for medical treatment
US12091397B2 · kind B2 · utility
0Cited by
19References
13Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 1, 2022 |
| Grant date | Sep 17, 2024 |
| Priority date | — |
| Expiry date | Aug 1, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D519/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides dihydroquinolinone compounds which bind to the ubiquitously expressed E3 ligase protein cereblon (CRBN) and alter the substrate specificity of the CRBN E3 ubiquitin ligase complex, resulting in breakdown of intrinsic downstream proteins. The disclosed compounds are useful for the treatment of cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.